Although ErbB2 is known to enhance breast cancer metastasis, the signaling events responsible for this remain elusive. a-Isozyme of protein kinase C (PKCa), which is involved in cancer development and progression, has been suggested to be activated by ErbB2 without direct evidence. In addition, the roles of PKCa in ErbB2-mediated cancer cell malignancy have not been clearly identified. In this study, we investigated whether ErbB2 can activate PKCa and determined what role PKCa plays in ErbB2-mediated breast cancer cell invasion. We expressed wild-type and mutant ErbB2 with altered signaling capacities in MDA-MB-435 breast cancer cells and revealed that overexpression or activation of ErbB2 in MDA-MB-435 cells upregulated and activated PKCa and that downregulation of ErbB2 by small-interfering RNA decreased the expression and activity of PKCa in BT474 breast cancer cells. These in vitro results were supported by data from breast cancer patient samples. In 150 breast cancer tumor samples, ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa membrane immunohistochemistry staining than that of ErbB2-low-expressing tumors. Mechanistically, we found that PKCa is co-immunoprecipitated with Src and PKCa expression and activity can be decreased by Src inhibitor PP2 and by the expression of a dominantnegative mutant of Src. Moreover, ErbB2-mediated upregulation of urokinase-type plasminogen activator receptor (uPAR) is reduced by either the PKCa inhibitor Go6976 or the Src inhibitor PP2, and the combination of Go6976 with PP2 is superior to either agent alone in suppressing uPAR expression and cell invasion. These results demonstrate that PKCa is critical for ErbB2-mediated cancer cell invasion and provide valuable insights for current and future PKCa and Src inhibitor clinical trials.
Introduction
ErbB2 (also known as HER2 or neu), a receptor tyrosine kinase, is amplified or overexpressed in approximately 30% of human breast cancers; and this overexpression has been shown to correlate with the number of lymph node metastases and a poor prognosis in patients (Yarden and Sliwkowski, 2001; Holbro and Hynes, 2004) . Overexpression of ErbB2 also leads to increased cancer invasion and metastasis in breast cancer cell lines and in animal models (Tan et al., 1997; Moody et al., 2002; Holbro et al., 2003) . The ErbB2 receptor tyrosine kinase has intrinsic tyrosine kinase activity (Yarden and Sliwkowski, 2001; Holbro et al., 2003) . Overexpression or mutation at the transmembrane domain of ErbB2 leads to autophosphorylation of tyrosine residues in its carboxy-terminal domain. The phosphorylated tyrosine residues then function as docking sites for ErbB2 downstream signaling molecules (Van der Geer et al., 1994; Holbro et al., 2003) . However, the overall picture of how ErbB2 exerts its function through its downstream signaling pathways and the signaling events responsible for ErbB2-enhanced cancer metastasis are not fully understood. As most patients with ErbB2-overexpressing breast cancer die from metastasis, unraveling the molecular mechanisms and signaling events that underlie ErbB2-mediated metastasis is urgently needed to help in the development of therapies for patients with ErbB2-overexpressing tumors.
Protein kinase C (PKC) is a family of serine/threonine kinases that are involved in the signaling pathways that regulate cell proliferation, differentiation, apoptosis, motility and adhesion (Dempsey et al., 2000; Parker and Murray-Rust, 2004) . The a-isozyme of PKC, PKCa, is widely expressed in various tissues, and PKCa expression and activity have been found to be higher in some types of tumors than in normal tissues (Lahn et al., 2004; Michie and Nakagawa, 2005) . Breast cancer cells engineered to express exogenous PKCa protein have been found to display a more aggressive phenotype (Ways et al., 1995) . In addition to the role PKCa plays in cell transformation and tumorigenesis, studies have indicated that elevated PKCa activity in some human carcinoma cells, including breast cancer cells, is associated with an increased invasive or metastatic potential (Morse-Gaudio et al., 1998; Masur et al., 2001) . As PKCa and other PKCs have been shown to play important roles in cancer development, these kinases have become one of the major targets of therapeutic interventions for various cancers (Sliva, 2004) . However, our knowledge on how PKCa is regulated and what role PKCa plays in cancer development are still limited. Although ErbB2 is known to phosphorylate and associate with phospholipase-g (PLCg) (Peles et al., 1991) , which may lead to the activation of PKCa, there is no direct evidence to support this. In addition, the role of PKCa in the malignant behavior of ErbB2-overexpressing cancer cells has not been clearly identified.
Src, an intracellular tyrosine kinase, is a critical component of the multiple signaling pathways that regulate a wide variety of cellular functions (Martin, 2001; Ishizawar and Parsons, 2004; Yeatman, 2004) . Activation of Src has been linked to the development of many human neoplasias, especially those of the colon, breast, lung and pancreas (Summy and Gallick, 2003) . Src binds to ErbB2 and is activated in ErbB2-overexpressing cancer cells (Muthuswamy and Muller, 1995; Nagata et al., 2004; Tan et al., 2005) . We recently showed that activation of ErbB2 can lead to increased Src protein synthesis and decreased Src protein degradation, resulting in Src protein upregulation and activation, which play critical roles in ErbB2-mediated breast cancer invasion and metastasis (Tan et al., 2005) .
The primary aim of this study was to investigate whether ErbB2 can activate PKCa and to determine what role PKCa plays in ErbB2-mediated breast cancer invasion and metastasis. We found that ErbB2 upregulates and activates PKCa through Src kinase, which is critical in ErbB2-mediated cancer cell invasion. Moreover, we demonstrated that ErbB2-mediated PKCa upregulation and activation is required for the ErbB2-mediated upregulation of the urokinase-type plasminogen activator receptor (uPAR), which may contribute to ErbB2-mediated cancer invasion and metastasis. Furthermore, we found that the combination of the PKCa inhibitor Go6976 and the Src inhibitor PP2 is superior to agents used individually in suppressing ErbB2-mediated uPAR upregulation and breast cancer cell invasion.
Results

Upregulation and activation of PKCa by ErbB2
To elucidate the ErbB2 downstream signals that contribute to ErbB2-mediated breast cancer metastasis, we previously established in ErbB2-low-expressing MDA-MB-435 human breast cancer cells stable transfectants expressing either two ErbB2 mutants (V659E, a constitutive active form of ErbB2; K753M, a kinasedefective mutant), a wild-type ErbB2 or a control pcDNA3 vector ( Figure 1a and Nagata et al., 2004; Tan et al., 2005) . We showed that the wild-type ErbB2-overexpressing 435.eB cells, ErbB2-activated V659E cells had increased tyrosine phosphorylation levels and kinase activities, and were more invasive in vitro and more metastatic in an animal model than the ErbB2 low-expressing parental MDA-MB-435 cells, control 435.neo cells and ErbB2 kinase-defective K753M cells (Tan et al., 2005) .
As PKCa has been shown to be involved in the development and progression of human breast cancer (Lahn et al., 2004) , we investigated whether ErbB2 can activate PKCa and what role PKCa plays in the ErbB2-mediated invasion of breast cancer cells. Immunoblotting was performed on the cell lysates from the MDA-MB-435 cells, the control 435.neo cells and the wild-type (435.eB) or mutant ErbB2 transfectants (V659E and K753M) to detect the phosphorylation levels on threonine 638 of PKCa, an indicator of PKCa activity (Bornancin and Parker, 1996; Parekh et al., 2000) , and the expression levels of PKCa protein in these cells (Figure 1a ). In the ErbB2-activated 435.eB and V659E cells, both the phosphorylation levels and the protein expression levels of PKCa were elevated compared with the levels of the ErbB2-low-expressing MDA-MB-435 cells, the 435.neo cells, and the ErbB2 kinase-defective K753M cells, indicating a higher level of total PKCa activity in the ErbB2-activated cells than in the ErbB2-low-expressing cells. Moreover, the localization of PKCa to the membrane compartment, which is another indicator of PKCa activation (Parker and Murray-Rust, 2004) , was more prevalent in the 435.eB and V659E cells than in the MDA-MB-435 cells, 435.neo cells, and K753M cells (Figure 1b) . In addition, the in vitro PKCa activity, detected by an immunocomplex kinase assay using histone H1 as the substrate, was higher in the 435.eB and V659E cells than in the MDA-MB-435, 435.neo and K753M cells (Figure 1c ). PKCa kinase activities paralleled with their protein expression levels in these cells, indicating that the higher PKCa kinase activities in 435.eB and V659E cells were likely due to the increased PKCa protein level rather than the increased kinase activity per PKCa molecule ( Figure 1c ). These results indicate that ErbB2 upregulates and activates PKCa in ErbB2-overexpressing or activated cells.
To further confirm these results, cells from another breast cancer cell line BT474, which overexpresses endogenous ErbB2, were transfected with small-interfering RNA (siRNA) to ErbB2. Immunoblotting results showed that the siRNA downregulated ErbB2 expression and subsequently reduced the phospho-PKCa levels and PKCa protein levels in BT474 cells (Figure 1d) . These results further demonstrate that ErbB2 activates PKCa in human breast cancer cells. To validate the clinical relevance of the finding, we examined whether ErbB2 overexpression correlates with PKCa activation in breast cancer patient samples. Tumor samples from 150 breast cancer patients were examined by immunohistochemistry staining of ErbB2 and PKCa. We found that ErbB2-overexpressing tumors showed significantly higher positive rates of PKCa cell membrane staining than did ErbB2-low-expressing tumors (Figure 1e and f), indicating that ErbB2-overexpressing tumor samples have an increased PKCa activation. In addition, ErbB2 activates PKCa via Src critical for cancer cell invasion M Tan et al protein lysates were extracted from 10 selected breast tumor samples of which five express ErbB2 at intermediate or high levels ( þ þ / þ þ þ ), five express ErbB2 at low levels (À/ þ ). Remarkably, immunoblotting with antibodies against ErbB2 and phospho-PKCa showed all five ErbB2 þ þ / þ þ þ tumors had increased PKCa phosphorylation, whereas only two of the five ErbB2 À/ þ tumors had detectable PKCa phoshphorylation ( Figure 1g ). These data further supports our finding that ErbB2 overexpression can lead to PKCa activation.
Upregulation and activation of PKCa by ErbB2 is critical for cancer cell invasion
To assess the role of PKCa activation in ErbB2-induced breast cancer cell invasion, we tested whether Go6976, a specific inhibitor of classic PKC isozymes (Huigsloot et al., 2003) , could inhibit the invasiveness of the ErbB2 transfectants that have PKCa activation. The 435.neo and 435.eB cells were treated with Go6976 or dimethylsulfoxide (DMSO) as the control and then transferred into transwell units for chemoinvasion assays. Go6976 effectively inhibited the PKCa phosphorylation in these cells ( ErbB2 activates PKCa via Src critical for cancer cell invasion M Tan et al directed to PKCa to downregulate PKCa expression, and invasion assays showed that downregulation of PKCa by siRNA markedly reduced the cell invasion ability of both cell lines. These results demonstrate that PKCa plays a critical role in ErbB2-induced cancer cell invasion.
ErbB2 activates PKCa through Src kinase
We recently demonstrated that ErbB2 overexpression and activation of its downstream signaling pathways can lead to Src protein upregulation and activation, both of which play critical roles in ErbB2-mediated breast cancer invasion and metastasis (Tan et al., 2005) . Coincidently, a recent report showed that Src is coimmunoprecipitated with estrogen receptor and PKCa in osteoblasts during differentiation (Longo et al., 2004) . We thus wondered whether Src and PKCa might work in concert to mediate the metastasis-promoting signals of ErbB2 in human breast cancer cells. To test whether PKCa is associated with Src in ErbB2-activated breast cancer cells, PKCa was immunoprecipitated with a PKCa-specific antibody from the lysates of wild-type and mutant ErbB2 transfectants and was then immunoblotted with Src and PKCa antibodies (Figure 3a) . A weak association between Src and PKCa was detected in ErbB2-low-expressing 435.neo cells and ErbB2-kinasedefective K753M cells. In contrast, in ErbB2-activated 435.eB and V659E cells, a strong Src and PKCa association was readily detected. Reverse immunoprecipitation (IP) with an Src antibody (Figure 3b ) also showed increased Src and PKCa association in ErbB2-activated cells. To test whether ErbB2 activates PKCa through Src, the 435.neo and 435.eB cells were treated with 5 or 10 mM PP2, an Src-specific inhibitor that has been shown to effectively block Src activation in these cells (Nagata et al., 2004; Tan et al., 2005) . The results showed that PP2 inhibited the expression of PKCa and reduced PKCa phosphorylation in ErbB2-overexpressing cells to levels similar to that in the 435.neo cells, whereas PP2 only inhibited PKCa phosphorylation to a lesser degree in 435.neo cells (Figure 4a) . Thus, Src kinase activation contributes to ErbB2-mediated PKCa upregulation and activation in ErbB2-overexpressing cells. The immunocomplexes were subjected to Src kinase assays by using enolase as the substrate. The Src and the b-actin protein levels were determined by immunoblotting. (c) Src inhibition led to decreased PKCa activity and Src activation led to increased PKCa activity in 435.eB cells. The protein lysates from the 435.eB and 435.eB cells stably expressing dominant-negative (eB.SrcDN) or constitutively activated Src (eB.SrcCA) were blotted with anti-phospho-PKCa, PKCa and anti-b-actin. Meanwhile, the cell lysates were precipitated with PKCa antibodies, and the immunocomplexes were subjected to PKCa kinase assays using histone H1 as the substrate.
ErbB2 activates
To further confirm that Src kinase is critical in ErbB2-mediated PKCa upregulation and activation in ErbB2-overexressing cancer cells, we stably expressed a constitutively active mutant (SrcCA) or a dominantnegative mutant (SrcDN) of Src in ErbB2-overexpressing 435.eB cells (Figure 4b, middle) (Nagata et al., 2004; Tan et al., 2005) . The activities of the activated or inhibited Src kinase in the SrcCA transfectants (eB.Src-CA) and SrcDN transfectants (eB.SrcDN) were confirmed with an immunocomplex Src kinase assay (Figure 4b, top) . To determine whether Src kinase regulates PKCa in ErbB2-activated cancer cells, immunoblotting was performed to detect the protein expression and phosphorylation levels of PKCa in the 435.eB cells and the Src mutant-transfected 435.eB cells (Figure 4c) . Compared with the levels in 435.eB cells, the protein expression and phosphorylation levels of PKCa were decreased in eB.SrcDN cells but the phosphorylation level was increased in eB.SrcCA cells. Moreover, an immunocomplex kinase assay showed lower PKCa activity in the eB.SrcDN cells than in the 435.eB cells but higher PKCa activity in the eB.SrcCA cells than in the 435.eB cells (Figure 4c ). These results indicate that Src is critical for ErbB2-mediated PKCa activation in ErbB2-activated breast cancer cells.
Src and PKCa activation lead to upregulation of uPAR in ErbB2-overexpressing breast cancer cells
Extensive laboratory and clinical studies have demonstrated that urokinase-type plasminogen activator (uPA) and its receptor (uPAR) play very important roles in cancer invasion and metastasis (Sidenius and Blasi, 2003) . In a previous study, we showed that overexpression of ErbB2 leads to increased activity of the extracellular matrix degradative-protease MMP9 (or type IV collagenase) in breast cancer cells (Tan et al., 1997) . To examine whether ErbB2 also upregulates uPAR, which may contribute to the enhanced invasion and metastatic potential of ErbB2-overexpressing breast cancer cells, we detected the protein expression levels of uPAR in ErbB2-low-expressing, metastatic MDA-MB-435 cells, and in the ErbB2-activated 435.eB cells and V659E cells, which have a further increased metastatic potential (Figure 5a ). Clearly, uPAR expression levels in the 435.eB and V659E cells were much higher than the uPAR expression level in the MDA-MB-435 cells, indicating that ErbB2 upregulates uPAR expression in these cells.
uPAR has also been shown to be upregulated by Src or PKC kinases respectively, this upregulation has been correlated with increased colon and breast cancer cell invasiveness (Johnson et al., 1999; Boyd et al., 2004) . Therefore, we examined whether Src and PKCa activation contributes to upregulation of uPAR in 435.eB and V659E cells. The 435.eB cells were treated with different concentrations of the PKCa inhibitor Go6976 (Figure 5b, top) or the Src inhibitor PP2 (Figure 5c , top). The uPAR expression levels decreased in a concentration-dependent manner in the Go6976-or PP2-treated 435.eB cells, indicating that activation of both Src and PKCa contributes to uPAR upregulation by ErbB2. We further confirmed these results by transfecting the dominant-negative mutant of PKCa (Figure 5b , bottom, left) or PKCa siRNA (Figure 5b , bottom, right) and the dominant-negative mutant of Src (Figure 5c, bottom) into the 435.eB cells. The expression of the PKCa dominant-negative mutant (PKCa.DN), PKCa siRNA, or the Src dominant-negative mutant (eB.SrcDN) reduced the expression levels of uPAR in ErbB2-overexpressing 435.eB cells, indicating that ErbB2-activated Src and PKCa is involved in upregulation of uPAR expression.
Combination of Src inhibitor and PKCa inhibitor inhibits cancer cell uPAR expression and invasion better than individual agents
Inhibition of Src by PP2 and by the expression of a dominant-negative Src mutant in 435.eB cells markedly 
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inhibited the invasion of the ErbB2-activated cells (Tan et al., 2005) . Similarly, in our current study, inhibition of PKCa by Go6976, the dominant-negative mutant PKCa or PKCa siRNA, significantly reduced the invasiveness of ErbB2-overexpressing 435.eB cells and BT474 cells (Figure 2 and data not shown) . Next, we examined whether the combination of a PKCa inhibitor and a Src inhibitor would be more effective than either agent alone in suppressing the invasiveness of the ErbB2-activated breast cancer cells.
We first studied whether the combination of the PKCa inhibitor Go6976 with the Src inhibitor PP2 would be superior to the individual agents in suppressing the expression of uPAR in ErbB2-activated breast cancer cells. The 435.eB cells were treated for 24 h with control DMSO, 5 mM Go6976, 10 mM PP2, or a combination of 2.5 mM Go6976 plus 5 mM PP2. As expected, treatment with either Go6976 or PP2 reduced the expression of uPAR in 435.eB cells (Figure 6a) . Notably, the combination of Go6976 and PP2, even at lower concentrations of each agent, was more effective in suppressing the expression of uPAR than when each agent was used alone at higher concentrations (Figure 6a) .
We then performed chemoinvasion assays to further examine whether the combination of Go6976 and PP2 was more effective than the individual agents in inhibiting the invasiveness of 435.eB cells. Compared with the DMSO control, treatment with either 5 mM Go6976 or 10 mM PP2 attenuated the invasiveness of the 435.eB cells by 46 or 42% (Figure 6b ). However, a combination of Go6976 and PP2, even at a lower concentration of each agent (Go6976 at 2.5 mM and PP2 at 5 mM), was more efficacious (58% inhibition) in suppressing the invasiveness of the 435.eB cells than were treatments with either of the agents alone at higher concentrations (Figure 6b ). When the concentrations of the agents in the combination treatment were the same as when each agent was used alone (Go6976 at 5 mM and PP2 at 10 mM), the inhibition of invasion was even more dramatic (83%, Figure 6b) . The difference between the inhibition achieved with the single agents and the combination agents was statistically significant. These results demonstrated that the combination of the PKCa inhibitor Go6976 and the Src inhibitor PP2 is superior to either agent alone in suppressing invasion of ErbB2-activated breast cancer cells.
Discussion
In this study, we found that upregulation and activation of PKCa by ErbB2 through Src is critical for ErbB2-mediated uPAR upregulation and breast cancer cell invasion. On the other hand, treatment with the combination of PKCa inhibitor Go6976 and Src inhibitor PP2 is superior to that with the individual agents in suppressing uPAR expression and in inhibiting the invasiveness of ErbB2-activated breast cancer cells.
Upregulation and activation of PKCa by ErbB2 is critical for breast cancer cell invasion
In addition to the role of PKCa in cell transformation and tumorigenesis, recent studies have shown that PKCa activation is associated with the increased invasive or metastatic potential of some human cancer cells, including breast cancer cells. It has been reported that ErbB2 can phosphorylate and associate with PLCg (Peles et al., 1991) , which leads to the assumption that ErbB2 also causes the activation of PKCa. In this study, we demonstrated that ErbB2 upregulates and activates PKCa and that PKCa is an important downstream signaling molecule that plays an essential role in mediating ErbB2-induced uPAR upregulation and cell invasion of breast cancer cells. Therefore, our study provides new insight into the roles of PKCa in ErbB2-mediated malignant phenotypes, especially in ErbB2-mediated cancer cell invasion, which may have valuable implications for developing new therapies for ErbB2-overexpressing cancers. The cells were treated with the indicated concentrations of Go6976, PP2 and a combination of Go6976 plus PP2 for 24 h and transferred to transwell units for chemoinvasion assays. The chemoinvasion assays were performed and the results were statistically analyzed as described in Figure 2a . **Po0.01; *Po0.05, compared with the results of the DMSO-treated cells.
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ErbB2 activates PKCa through Src kinase
In the classic model of PKC activation by receptor tyrosine kinases, PLCg cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) to diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3 then stimulates the opening of Ca 2 þ channels and increases the cytoplasmic concentration of Ca 2 þ . DAG and Ca 2 þ , along with other cofactors, lead to the activation of classic PKCs (Nishizuka, 1992; Parker and Murray-Rust, 2004) . One possible mechanism of PKCa activation by ErbB2 is that ErbB2 phosphorylates and associates with PLCg and leads to PKC activation (Peles et al., 1991) . However, recent studies have revealed that multiple signaling pathways may modulate the activation and phosphorylation of PKCs (Parekh et al., 2000; Parker and Murray-Rust, 2004; Michie and Nakagawa, 2005) . As PKCa plays a critical role in ErbB2-induced cancer cell invasion (Figure 2 ), we explored other mechanisms that may also be involved in PKCa activation.
Although it has been shown that Src is co-immunoprecipitated with PKCa in osteoblasts during differentiation (Longo et al., 2004) , Src-PKCa association in other types of cells, including cancer cells, has not been reported. In this study, we found that Src is coimmunoprecipitated with PKCa and that Src kinase activity contributes to PKCa activation by ErbB2 in human breast cancer cells. These results suggest that Src kinase is another important regulator of PKCa activation in breast cancer cells. These findings raise many questions that need to be further investigated in the future: Does Src directly or indirectly interact with PKCa? What is the biological significance of the interaction? Does Src phosphorylate PKCa? If so, what is the biological consequence of the phosphorylation? Answers to these questions will significantly further our understanding of the crosstalk between Src and PKCa and the roles of Src and PKCa in ErbB2-mediated cancer cell malignant phenotypes and these problems are currently under investigation in our laboratory. Nevertheless, our study provides new insight into the understanding of the mechanisms of PKCa activation and the role of PKCa in ErbB2-overexpressing breast cancer cells.
Therapeutic implications for Src inhibitor and PKCa inhibitor in suppressing cancer metastasis
Numerous studies have demonstrated that uPA and its receptor uPAR play very important roles in cancer invasion and metastasis (Sidenius and Blasi, 2003) . The uPAR expression levels correlate with tumor progression and poor patient prognosis. Expression of uPAR exogenously enhances the metastatic potential of cancer cells. Inhibition of uPA and/or interruption of uPA/ uPAR binding reduces metastasis in animal models, and tumor growth and progression are slower in plasminogen-and uPA-deficient mice than in wild-type mice (Sidenius and Blasi, 2003) . In our study, we found that ErbB2 upregulates uPAR expression in human breast cancer cells, which is in line with the previous finding that ErbB2 upregulates uPA in lung cancer cells (Gum et al., 1995) . These results further support the finding that the uPA/uPAR system contributes to a higher metastatic potential in ErbB2-overexpressing cancer cells. Cancer cells treated with either PKCa inhibitors or Src inhibitor PP2 showed reduced expression of uPAR and an inhibition of cancer cell invasion (Johnson et al., 1999; Boyd et al., 2004) . In this study, inhibition of PKCa or Src in ErbB2-overexpressing breast cancer cells by chemical inhibitors, dominant-negative mutants or siRNA decreased uPAR expression and cancer cell invasion, indicating that ErbB2-activated Src and PKCa kinases play critical roles in the ErbB2-mediated upregulation of uPAR and the enhancement of cancer cell invasiveness.
Effective anticancer treatment is likely to involve combinations of multiple agents because tumor progression is a multistep process involving multiple genes and complicated signaling networks (Vogelstein et al., 1988; de Bono et al., 2003) . For example, our group recently found that combined trastuzumab and paclitaxel treatment better inhibited ErbB2-mediated angiogenesis in breast cancer by more effectively inhibiting Akt than did either treatment alone (Klos et al., 2003) . Here, we showed that combined treatment with the PKCa inhibitor Go6976 and the Src inhibitor PP2 has an effect superior to that of either agent alone in suppressing uPAR expression and cancer cell invasion. These results support the notion that Src and PKCa work cooperatively to mediate the ErbB2-induced cancer cell invasion and metastasis. These findings are likely to have a significant impact on the design of future clinical trials and target-based therapy consisting of PKCa and Src inhibitors.
Materials and methods
Antibodies and reagents
Antibodies and reagents were purchased from commercial sources: antibodies against Src and ErbB2 (Ab3) were from Oncogene Science (Cambridge, MA, USA); anti-PKCa antibodies were from BD Transduction Laboratory (San Diego, CA, USA); antibodies against phospho-PKCa (Threonine 638) were from Cell Signaling Technology (Beverly, MA, USA); antibodies against biotinylated anti-human uPAR were from R&D Systems (Minneapolis, MN, USA); anti-ErbB3 antibodies were from NeoMarkers (Fremont, CA, USA); and the Src inhibitor PP2 and PKCa inhibitor Go6976 were from Calbiochem (San Diego, CA, USA). Antibodies against bactin, Src kinase substrate elonase and PKCa kinase substrate histone H1 were from Sigma (St Louis, MO, USA).
Cell lines and cell cultures MDA-MB-435 human breast cancer cells, 435.eB cells (MDA-MB-435 cells stably expressing wild-type ErbB2) and 435.neo control cells were obtained, established and cultured as previously reported (Yu et al., 1996) . The ErbB2 mutants (V659E and K753M) were subcloned from the pSV2 vectors into pcDNA3 expression vectors (Invitrogen, Carlsbad, CA, USA) in which transcription is driven by a cytomegalovirus promoter. The resulting plasmids were transfected into MDA-MB-435 cells as previously described (Yu et al., 1998) , and the stable transfectants were selected by adding G418 (Geneticin; ErbB2 activates PKCa via Src critical for cancer cell invasion M Tan et al Life Technologies, Rockville, MD, USA). Immunoblotting was performed to identify transfectants that expressed the ErbB2 protein. The dominant-negative mutant sequence of Src was subcloned from the expression vector pcR295 into the pireSpuro2 vector (Clontech, Palo Alto, CA, USA). The resulting plasmid (DNSrc) was transfected into 435.eB or 435.neo cells, and the transfectants were selected using puromycin (Clontech). The expression vector of the dominant-negative mutant of PKCa (pEF-PKCaK/R) and the control vector pEF-neo were transiently transfected into 435.eB cells. All breast cancer cells used in this study were grown in Dulbecco's modified Eagle's medium and Ham's F-12 medium (Life Technologies).
Immunoblot and IP analyses
Western blot and IP analyses were performed as previously described (Tan et al., 1999) . The protein inputs in these analyses were normalized by loading an equal amount of total protein lysates onto the sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) gels, and the b-actin served as a protein-loading control. The nonradioactive signals were quantified by an Alpha Imager 2000 (Alpha Innotech, San Leandro, CA, USA). The radioactive signals were quantified with a phosphoimager (Molecular Dynamics, Sunnyvale, CA, USA).
Separation of membrane-bound and cytosolic proteins Cells were lysed in saponin buffer (0.01% saponin, 10 mM TrisHCl at pH 7.4, 140 mM NaCl, 5 mM EDTA, 2 mM EGTA, 0.2 mM sodium vanadate, 50 mM NaF, 25 mM b-glycerophosphate) containing a protease inhibitor cocktail (Sigma). Proteins were extracted by placing the lysates on ice for 20 min, and samples were centrifuged at 13 000 g for 30 min at 41C. Then, the saponin-soluble pool (cytosolic pool) was collected. The remaining pellets were rinsed once with saponin buffer, extracted in IP buffer, and centrifuged to remove the insoluble materials. Finally, the supernatant (membrane-bound pool) was collected (Palka and Green, 1997) .
In vitro cell invasion assay Cell invasion was assayed as previously described (Tan et al., 1997) .
Src kinase assay Src kinase activity was assayed as previously described (Tan et al., 2005) .
PKCa kinase assay
The cells were lysed and immunoprecipitated with anti-PKCa antibodies. The immunoprecipitates were washed three times with IP buffer and twice with a kinase buffer. Kinase activity was assayed by incubating the immunoprecipitates with 40 ml of kinase buffer containing 20 mM Tris-HCl, pH 7.4, 10 mM MgCl 2 , 10 mM cold ATP, 400 mg/ml of histone H1 and 2.5 mCi of [g-32 P]ATP. After 10 min at 301C, the reaction was terminated by adding an equal volume of the 2 Â SDS sample buffer and boiling it for 5 min. The samples were subjected to SDS-PAGE. The 32 P-labeled enolase was visualized by autoradiography.
RNA interference siRNAs were designed to target ErbB2-specific sequences as previously described (Tan et al., 2005) . BT474 breast cancer cells were cultured to B30% confluence and then transfected with ErbB2 siRNA. After 3 h of transfection, the cells were incubated with serum-containing medium, and 48 h after transfection the cell lysates were collected for immunoblotting. An siRNA concentration of 67 nM was able to greatly decrease ErbB2 protein levels compared to that in the control GFP siRNA-or mock-transfected cells.
Patient tumor samples
Tumor samples were collected from 150 patients with primary invasive breast cancer that was diagnosed and treated at The Cancer Hospital, FuDan University (Shanghai, China) from 1988 to 1991 . Immunohistochemistry analysis with antibodies against PKCa was performed on 5 mM tumor sections, as described previously . Positive staining for PKCa was defined as more than 10% of cancer cells showing cell membrane staining. ErbB2 was detected and graded with the DAKO HercepTest (DAKO, Carpinteria, CA, USA), and the þ þ þ staining was defined as ErbB2 positive. Statistical analyses were performed with Prism Software (GraphPad Software, San Diego, CA, USA). P-values less than 0.05 as calculated with Fisher's exact test were considered statistically significant.
